NewsRoom Articles - Page 111 of 207

WednesdayMar 30, 2022 1:55 pm

Monitoring Glucose Levels May Help Manage Weight

Managing one’s weight may be a bit difficult, especially when it comes to consistency. However, did you know that continuous glucose monitoring (CGM) technology can help? CGM is usually used by individuals with diabetes to help manage and monitor their blood sugar. However, the demand for personalized nutrition has seen continuous glucose monitoring devices being used outside the diabetes space. For instance, companies such as NutriSense promote their CGM product as an overall health solution for everything, including weight loss. NutriSense is focused on improving metabolic health. The company leverages its advanced continuous glucose monitoring technology to personalize individual nutrition.…

WednesdayMar 30, 2022 9:00 am

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD Silo currently has under review four U.S.…

TuesdayMar 29, 2022 1:48 pm

Study Finds That Patients with PTSD, Bipolar Disorder May Benefit from Telehealth Treatment

Research has found that a virtual connection to a psychiatrist may help people living in rural communities and grappling with bipolar disorder and post-traumatic stress disorder acquire effective care. The randomized study, which was carried out before the coronavirus pandemic, examined how patients’ clinical characteristics impacted their experience with telehealth as well as how well they observed their treatment course. For their study, the researchers analyzed data from about 1,000 participants with bipolar disorder, post-traumatic stress disorder or both, from 24 clinics in Arkansas, Washington and Michigan. The data was obtained from the Study to Promote Innovation in Rural Integrated…

TuesdayMar 29, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer CNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in June 2020 Berubicin is a novel anthracycline capable of crossing the blood-brain barrier The company received approval from Switzerland’s swissethics organization for Berubicin trials there, boosting CNS’s efforts at a global response to…

MondayMar 28, 2022 2:22 pm

NIH Launches New Pediatric Cancer Biomarker Testing Program

The National Institutes of Health, under the National Cancer Institute, recently unveiled a new initiative that will provide biomarker testing to young adults, adolescents and children who have been diagnosed with tumors afflicting the central nervous system. The tests will be offered to pediatric patients with this cancer who are receiving treatment at hospitals affiliated with a clinical trial group supported by the National Cancer Institute known as the Children’s Oncology Group, which includes more than 200 institutions and hospitals that treat children diagnosed with various cancers in the United States. Those eligible will receive tumor molecular characterization without charge…

MondayMar 28, 2022 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials The company is targeting nicotine addiction in tobacco smokers Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF)…

FridayMar 25, 2022 11:36 am

Scientists Explore Possible Link Between Coronavirus Infections, Rising Diabetes Cases

During the pandemic, researchers discovered that the coronavirus infection worsened the condition of individuals who already had diabetes, leading to severe complications. Researchers are now looking into the existence of a link between the coronavirus and diabetes, with new evidence showing that the coronavirus may attack cells that produce insulin in the pancreas. The researchers hypothesize that this could be what triggers temporary diabetes in susceptible individuals. The increase in the number of diabetes cases may also reflect situations involving restrictions imposed during the pandemic, which include inactivity and unhealthy eating habits in individuals who were already at risk for…

ThursdayMar 24, 2022 3:21 pm

Survey Data Shows More Than 230M Workdays Missed Every Year Due to AUD

Data from a recently conducted study shows that about 9% of adults in America who work full-time may suffer from alcohol use disorder. Alcohol use disorder (AUD) is a condition characterized by an impaired ability to control or stop the use of alcohol, despite adverse consequences in an individual’s health, work life or social life. The survey, which involved more than 110,000 adults in the United States, was carried out by researchers from the School of Medicine at Washington University in St. Louis. Their objective was to determine the relationship between missing work and the heavy use of alcohol. The…

ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

WednesdayMar 23, 2022 3:23 pm

American Hospital Association Calls on Congress to Address Shortage of Behavioral Healthcare Providers

The American Hospital Association (AHA) is urging the Senate Finance Committee to strengthen financial support programs that assist healthcare systems to address the shortage of providers of behavioral healthcare. The organization recently penned a statement to Congress highlighting how the coronavirus pandemic increased the demand for care and aggravated the behavioral health crisis. All individuals, but particularly children and adolescents, are experiencing high rates of depression, anxiety and substance use disorder, among other mental issues. However, barriers hinder them from acquiring proper care. Currently, health systems and hospitals are finding it hard to offer sufficient behavioral healthcare services to youths…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Monitoring Glucose Levels May Help Manage Weight

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Study Finds That Patients with PTSD, Bipolar Disorder May Benefit from Telehealth Treatment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

NIH Launches New Pediatric Cancer Biomarker Testing Program

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Scientists Explore Possible Link Between Coronavirus Infections, Rising Diabetes Cases

Survey Data Shows More Than 230M Workdays Missed Every Year Due to AUD

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

American Hospital Association Calls on Congress to Address Shortage of Behavioral Healthcare Providers

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search